Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis

Ruben A. Mesa, Ayalew Tefferi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Managing patients with myelofibrosis (MF) (both those with primary myelofibrosis or having evolved from an antecedent polycythemia vera or essential thrombocythemia) present many challenges to the hematologist. MF patients suffer from a variable, but severe range of disease manifestations including massive splenomegaly, cytopenias, significant constitutional symptoms, possible transformation to blast phase and premature death. Cure is achievable through allogeneic stem cell transplantation; yet, this therapy is either inappropriate or not an option for most patients. Current available therapies are palliative, but can sometimes be of significant value to MF patients. The discovery of the JAK2-V617F mutation, and other pathogenetic insights into the pathophysiology of myeloproliferative neoplasms, has ushered in an era of potential new therapies for MF. Over a dozen JAK2 inhibitors are in development, with the leading compounds such as INCB018424, TG101348 and others showing promising early results particularly for control of disease associated splenomegaly and symptoms. Parallel trials with immunomodulatory therapy for MF associated anemia and stromal manifestations of the disease are continuing. The future may well see the approval of a range of agents for MF patients, with differing mechanisms of action, efficacy and toxicity profiles.

Original languageEnglish (US)
Pages (from-to)471-479
Number of pages9
JournalExpert Opinion on Emerging Drugs
Volume14
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Drug Therapy
Splenomegaly
Blast Crisis
Premature Mortality
Immunomodulation
Stem Cell Transplantation
Proxy
Palliative Care
Anemia
Mutation
Therapeutics

Keywords

  • IMID
  • JAK2
  • Myelofibrosis
  • Myeloproliferative

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. / Mesa, Ruben A.; Tefferi, Ayalew.

In: Expert Opinion on Emerging Drugs, Vol. 14, No. 3, 09.2009, p. 471-479.

Research output: Contribution to journalArticle

@article{8b0dc712904644d8a68cadaa60e7436b,
title = "Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis",
abstract = "Managing patients with myelofibrosis (MF) (both those with primary myelofibrosis or having evolved from an antecedent polycythemia vera or essential thrombocythemia) present many challenges to the hematologist. MF patients suffer from a variable, but severe range of disease manifestations including massive splenomegaly, cytopenias, significant constitutional symptoms, possible transformation to blast phase and premature death. Cure is achievable through allogeneic stem cell transplantation; yet, this therapy is either inappropriate or not an option for most patients. Current available therapies are palliative, but can sometimes be of significant value to MF patients. The discovery of the JAK2-V617F mutation, and other pathogenetic insights into the pathophysiology of myeloproliferative neoplasms, has ushered in an era of potential new therapies for MF. Over a dozen JAK2 inhibitors are in development, with the leading compounds such as INCB018424, TG101348 and others showing promising early results particularly for control of disease associated splenomegaly and symptoms. Parallel trials with immunomodulatory therapy for MF associated anemia and stromal manifestations of the disease are continuing. The future may well see the approval of a range of agents for MF patients, with differing mechanisms of action, efficacy and toxicity profiles.",
keywords = "IMID, JAK2, Myelofibrosis, Myeloproliferative",
author = "Mesa, {Ruben A.} and Ayalew Tefferi",
year = "2009",
month = "9",
doi = "10.1517/14728210903066809",
language = "English (US)",
volume = "14",
pages = "471--479",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis

AU - Mesa, Ruben A.

AU - Tefferi, Ayalew

PY - 2009/9

Y1 - 2009/9

N2 - Managing patients with myelofibrosis (MF) (both those with primary myelofibrosis or having evolved from an antecedent polycythemia vera or essential thrombocythemia) present many challenges to the hematologist. MF patients suffer from a variable, but severe range of disease manifestations including massive splenomegaly, cytopenias, significant constitutional symptoms, possible transformation to blast phase and premature death. Cure is achievable through allogeneic stem cell transplantation; yet, this therapy is either inappropriate or not an option for most patients. Current available therapies are palliative, but can sometimes be of significant value to MF patients. The discovery of the JAK2-V617F mutation, and other pathogenetic insights into the pathophysiology of myeloproliferative neoplasms, has ushered in an era of potential new therapies for MF. Over a dozen JAK2 inhibitors are in development, with the leading compounds such as INCB018424, TG101348 and others showing promising early results particularly for control of disease associated splenomegaly and symptoms. Parallel trials with immunomodulatory therapy for MF associated anemia and stromal manifestations of the disease are continuing. The future may well see the approval of a range of agents for MF patients, with differing mechanisms of action, efficacy and toxicity profiles.

AB - Managing patients with myelofibrosis (MF) (both those with primary myelofibrosis or having evolved from an antecedent polycythemia vera or essential thrombocythemia) present many challenges to the hematologist. MF patients suffer from a variable, but severe range of disease manifestations including massive splenomegaly, cytopenias, significant constitutional symptoms, possible transformation to blast phase and premature death. Cure is achievable through allogeneic stem cell transplantation; yet, this therapy is either inappropriate or not an option for most patients. Current available therapies are palliative, but can sometimes be of significant value to MF patients. The discovery of the JAK2-V617F mutation, and other pathogenetic insights into the pathophysiology of myeloproliferative neoplasms, has ushered in an era of potential new therapies for MF. Over a dozen JAK2 inhibitors are in development, with the leading compounds such as INCB018424, TG101348 and others showing promising early results particularly for control of disease associated splenomegaly and symptoms. Parallel trials with immunomodulatory therapy for MF associated anemia and stromal manifestations of the disease are continuing. The future may well see the approval of a range of agents for MF patients, with differing mechanisms of action, efficacy and toxicity profiles.

KW - IMID

KW - JAK2

KW - Myelofibrosis

KW - Myeloproliferative

UR - http://www.scopus.com/inward/record.url?scp=69949167616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949167616&partnerID=8YFLogxK

U2 - 10.1517/14728210903066809

DO - 10.1517/14728210903066809

M3 - Article

C2 - 19552608

AN - SCOPUS:69949167616

VL - 14

SP - 471

EP - 479

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -